In 2019, Fang and collaborators showed that DOX, an important class of drugs for treating cancer which unfortunately promotes cardiovascular injury, upregulates the Nrf2/HO-1 pathway, mediating heme degradation and free iron release, and resulting in cell death [152]. This evidence concerns the gene HMOX1 and cancer.